Cumulus Neuroscience Welcomes Dr. Ricardo Sáinz Fuertes as New Board Chair

Cumulus Neuroscience, a prominent name in the realm of digital health, has officially named Dr. Ricardo Sáinz Fuertes as the new Chair of its Board of Directors. This key leadership change was announced on January 8, 2026, marking a new chapter for the company as it continues to innovate and evolve in the field of neuroscience clinical trials and patient care.

Dr. Sáinz Fuertes replaces Dr. Ruth McKernan, who held the position for six years and played a critical role in steering the company’s direction. Under her guidance, Cumulus built a strong foundation, including the establishment of the Cumulus Pharma Advisory Group that collaborated with top-tier pharmaceutical companies to enhance the NeuLogiq® Platform. CEO Tina Sampath expressed gratitude for Dr. McKernan's contributions, highlighting her pioneering work in digital biomarkers and her vision for addressing challenges in Central Nervous System (CNS) drug discovery.

As Dr. McKernan steps down, she leaves behind a legacy as a founder and chair who significantly advanced the company's mission. "I have truly enjoyed my time at Cumulus and look forward to seeing how the company flourishes under Ricardo's leadership," McKernan remarked, extending her best wishes for the company's future.

Dr. Sáinz Fuertes comes to the position with extensive expertise, currently serving as the Global Director of Digital Health Solutions at Eisai since May 2023. His background combines elements of psychiatry, neuroscience, and digital health innovation—making him a fitting choice to lead Cumulus as it transitions toward a fully commercial digital biomarker company. In his acceptance, he expressed, "I'm honored to join the Cumulus Board as chair and help advance their mission through patient-centered digital transformation."

One of the flagship products of Cumulus, the NeuLogiq® Platform, is designed in conjunction with industry leaders to track brain function dynamically. This sophisticated platform allows patients to engage with gamified behavioral tasks while wearing a headset that records EEG brain waves. Such advances are vital for biopharma companies to collect objective data, thereby ensuring a better understanding of brain network activities over time.

Looking ahead, Dr. Sáinz Fuertes anticipates steering Cumulus toward wider acceptance of the NeuLogiq Platform, aiming to fulfill the critical need for precise and sensitive tools in CNS clinical studies. This strategic focus will be pivotal as the company works to develop vital therapies for patients grappling with neurodegenerative diseases and neuropsychiatric conditions.

Cumulus Neuroscience is recognized globally for its cutting-edge brain health technology, with a mission centered around expediting treatment development for various neuropsychiatric and neurodegenerative disorders. The company’s innovative approach combines reliable, scalable, and compliant solutions to measure brain function effectively in real-world settings.

In an era where digital health solutions are increasingly crucial, Cumulus stands out as a leader in harnessing data to introduce significant advancements in patient care. Dr. Sáinz Fuertes' appointment as Chair is not only a progressive step for the organization but a promising signal for future innovation in neuroscience and digital health spheres.

For more details about Cumulus Neuroscience and its initiatives, visit www.cumulusneuro.com.